Roivant Sciences (ROIV)

• Market cap: $20.4B
• 1 day: 3.67%
• 5 days: 1.03%
• 1 month: 8.03%
• 3 months: 31.96%
• 6 months: 45.71%
• Year to date: 30.1%
• 1 year: 145.52%
• 5 years: 205.13%
• 10 years: 205.13%
• Sector: Healthcare
• Industry: Biotechnology

About: Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Employees: 750